Download presentation
Presentation is loading. Please wait.
Published byEmily Stewart Modified over 9 years ago
1
Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a FNKV
2
Prostate cancer Epidemiology: Incidence: ČR 80/100 000 USA 120/100 000 Mortality: ČR 15/100 000
3
Prostate cancer Epidemiology: ČR
4
Prostate cancer Epidemiology: Prostate cancer: EU – 2 nd in men mortality for cancer (1 st lung cancer) USA – 1 st in men mortality for cancer
5
Prostate cancer Epidemiology: Risk factors: Increasing age, race (afroamericans), heredity Exogenous factors: Diete, UV radiation, alcohol consumption, risk sexual behavior, infection (HPV?)
6
Prostate cancer Epidemiology: Increasing age: The prostate cancer incidence in per cent generaly correlates to the patient´s age
7
Prostate cancer Epidemiology: Basic check-up: Discussion about the mass screening Expenses Unapparent (asymptomatic) tumors treatment
8
Prostate cancer Epidemiology: Basic check-up: Recommended: Screening in risk population – positive family history Positive clinical symptoms In patients who actively visit doctor and ask for check-up
9
Prostate cancer Epidemiology: Basic check-up: Recommended: Digital rectal examination in all men in all time PSA only in recommended case (previous slide)
10
Prostate cancer Epidemiology: Basic check-up: Recommended: Start PSA test between 45-50 years Start PSA test in the positive family history case between 40-45 years
11
Prostate cancer Epidemiology: Basic check-up: Recommended: In patient unfit for treatment (age, co-morbidity, weak life prognosis) there is NO INDICATION FOR PSA TESTING !!!
12
Prostate cancer Diagnosis: Basic exams: Digital rectal exam (DRE) Prostate specific antigen (PSA)
13
Prostate cancer Diagnosis: DRE:
14
Prostate cancer Diagnosis: DRE: Prostate shape, volume, consistence, demarcation Semen vesicules examination Bimanual palpation (in anesthesia)
15
Prostate cancer Diagnosis: DRE: 95 % of cancer originates from the peripheral zone of prostate Suitable for palpation
16
Prostate cancer Diagnosis: Prostate specific antigen (PSA): 33 kD molecular weigh glycoprotein (Proteases enzyme) Gene in 19 th chromosome Half-life period 3-5 days
17
Prostate cancer Diagnosis: Prostate specific antigen (PSA): Produced almost exclusively by the epithelial cells of the prostate Prostate-specific marker, no cancer-specific High sperm concentration
18
Prostate cancer Diagnosis: Prostate specific antigen (PSA): Venous blood sample The exact cut-off level of what is considered to be a normal PSA value has yet to be determined Generally used cut-off level: 4-4.2 ng/ml Values of approximately < 2-3 ng/ml are often used for younger men
19
Prostate cancer Diagnosis: Prostate cancer diagnosis: PSA elevation or DRE suspicion Prostate biopsy – Transrectal USG (TRUS biopsy) PCA3 (Prostate Cancer Antigen 3)
20
Prostate cancer Diagnosis: TRUS prostate biopsy: Prostate morphology Peripheral zone biopsy Min. of 12 samples, according to prostate volume correction In case of negative first biopsy repet one is needed
21
Prostate cancer Diagnosis: TRUS prostate biopsy: Biopsy gun
22
Prostate cancer Diagnosis: Prostate Cancer Antigen 3 (PCA3): Genetic marker Cancer - specific Urine sampled after DRE Additional test, no standard
23
Prostate cancer Diagnosis: Prostate Cancer Antigen 3 (PCA3): Indications: PSA elevation and negative prostate biopsy Decision on re-biopsy No treatment in PCA3 elevation only
24
Prostate cancer Diagnosis: Prostate Cancer Antigen 3 (PCA3): Some studies present the PCA3 level and Gleason Score correlation (tumor aggressiveness)
25
Prostate cancer Diagnosis: Morphology: Histological types: Acinar adenocarcinoma Papilar (ductal) carcinoma Small cell carcinoma Ring cell carcinoma Sarcomatoid carcinoma (No PSA production)
26
Prostate cancer Diagnosis: Grading: Gleason grade
27
Prostate cancer Diagnosis: Grading: Gleason score: The Gleason score is the sum of the most dominant and second most dominant (in terms of volume) Gleason grade. If only one grade is present, the primary grade is doubled. Examples include: GS 2+2, GS 3+4, GS 4+3 etc.
28
Prostate cancer Diagnosis: Grading: Gleason scoce correlates to the tumor dedifferentiation (aggressiveness)
29
Prostate cancer Diagnosis: Staging: DRE TRUS CT scan and bone scan in PSA value > 20 ng/ml (in case of GS ≥ 7 even in PSA value > 10 ng/ml) MRI
30
Prostate cancer Diagnosis: Staging: TNM classification: T1 – Clinically unapparent tumour not palpable or visible by imaging T2 – Tumour confined within the prostate T3 – Tumour extends through the prostatic capsule T4 – Tumour is fixed or invades adjacent structures other than seminal vesicles
31
Prostate cancer Diagnosis: Staging: TNM classification: N1 – Lymph nodes involvement M1 – Distant metastases (non-regional lymph nodes, bones, liver, lungs)
32
Prostate cancer Diagnosis: Staging:
33
Prostate cancer Diagnosis: Staging:
34
Prostate cancer Diagnosis: Prognotic factors: Gleason score (Tumor aggressiveness) PSA level Age and biological condition
35
Prostate cancer Treatment: Localised prostate cancer (T1-T2): Watchful Waiting / Active Monitoring Surgery – Radical Prostatectomy Radiation therapy (Tele, Brachy) Experimental – Kryosurgery, HIFU ( High Intensity Focused Ultrasound)
36
Prostate cancer Treatment: Watchful waiting (WW): Deferred treatment Treatment starts in case of clinical symptoms developement No cure intention Suitable for patients with shorter life expectancy
37
Prostate cancer Treatment: Active surveillance or monitoring (AS): Deferred treatment with cure intention Active monitoring of tumor activity (PSA, repet TRUS biopsy – progression of number of positive samples, Gleason Score progression etc.) Treatment starts at the moment of progression Well-informed patient only
38
Prostate cancer Treatment: Radical prostatectomy: Complete prostate, prostate capsule, vesicles and prostate part of urethra removal Lymphadenectomy only in indicated cases
39
Prostate cancer Treatment: Radical prostatectomy: Retropubic access Open surgery Laparoscopy Robot - assisted
40
Prostate cancer Treatment: Radical prostatectomy: T1-2 stages „Younger“ patients – life expectancy > 10 years
41
Prostate cancer Treatment: Radical radiation therapy: Teleradiotherapy: External beam of radiation of prostate, vesicles and surrounding tissues, in special cases of regional lymph nodes
42
Prostate cancer Treatment: Teleradiotherapy: Linear accelerators Three-dimensional conformal radiotherapy (3D- CRT) and intensity modulated external beam radiotherapy (IMRT) Dose escalation Adverse events minimalization
43
Prostate cancer Treatment: Teleradiotherapy: Innovative techniques: Proton beam accelerators Carbon ion beam accelerators
44
Prostate cancer Treatment: Teleradiotherapy: T1-2 stages and no plan of radical prostatectomy T3-T4, N1 stages
45
Prostate cancer Treatment: Transperineal Brachytherapy: Effective technique in T1-2 stages, PSA ≤ 10 ng/ml, GS ≤ 6 and prostate volume ≤ 50-60 ml
46
Prostate cancer Treatment: Transperineal Brachytherapy: Transperineal access, USG guided technique Permanent radioactive implats application (Palladium-103)
47
Prostate cancer Treatment: Transperineal Brachytherapy: Local anesthesia only One-shot application
48
Prostate cancer Treatment: Local advanced prostate cancer (T3-T4, N1): Watchful waiting Radiation therapy (Teleradiotherapy)
49
Prostate cancer Treatment: Metastatis prostate cancer: Watchful waiting Hormonal therapy Chemotherapy Palliative therapy
50
Prostate cancer Treatment: Hormonal therapy: Stage M1 Endogeneous androgen production: Testicles 90 – 95 % Adrenal glands 5 – 10 %
51
Prostate cancer Treatment: Hormonal therapy: Testosterone is essential for the prostate tissue growth and prostate cancer growth as well http://www.oncoprof.net
52
Prostate cancer Treatment: Hormonal therapy: LHRH analogs – central blocade Antinadrogens – peripheral blocade Ketokonazole – adrenal production blocade Surgical– bilateral orchiectomy Combinations
53
Prostate cancer Treatment: Chemotherapy: Taxans – Docetaxel, Cabazitaxel Estramustin Treatment of relapse after hormonal therapy in stage M1
54
Prostate cancer Treatment: Palliative therapeutic options: Bone metastases: (Bone resorption inactivation) Bisphosphonates Denosumab Painful bone metastases – i.v. aplication of radionuclides (Stroncium)
55
Prostate cancer Treatment: Palliative therapeutic options: Urinaty retention: TURP (Transurethral Prostate Resection) Urethral catheter, epicystostomia Ureteral stents Nephrostomy tube
56
Prostate cancer Treatment: Palliative therapeutic options: Opoids Blood supplementation Corticosteroids Surgical treatment of pathological bone fractures and vertebral compression
57
Prostate cancer Follow-up : Basic periodic exam.: PSA DRE
58
Prostate cancer Follow-up : PSA elevation - restaging CT Bone scan
59
Prostate cancer Follow-up : In special cases: PET – CT MRI
60
Prostate cancer Prognosis: Generally excellent (in T1-N1 stage generally complete cure) Majority of patients in M1 stage survive years! Prognosis estimation: Entering Gleason score, PSA, biological condition
61
Prostate cancer Contact: jan.pokorny@fnkv.cz
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.